Medicis Sues Lupin To Halt Generic Acne Drug

By Leigh Kamping-Carder

Law360, New York (February 03, 2010, 2:44 PM ET) -- Skin health specialist Medicis Pharmaceutical Corp. has hauled Lupin Ltd. into court over the Indian drugmaker's plan to manufacture generic versions of all five approved dosages of acne drug Solodyn.

Medicis filed an amended complaint Tuesday in the U.S. District Court for the District of Maryland, broadening its claims of patent infringement against Mumbai-based Lupin and its U.S. subsidiary Lupin Pharmaceuticals Inc.

Medicis claims Lupin has infringed U.S. Patent Number 5,908,838, covering extended release tablets for acne treatment, by seeking to manufacture a generic Solodyn before...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles